(Q38500054)

3 September 2017

title

Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial (English)

1 reference

3 September 2017

Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial (English)

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEQ291

12 July 2024

7

Vikas Agarwal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837499

12 July 2024

author name string

Sudeep Kumar

2

1 reference

3 September 2017

Uttam Singh

5

1 reference

3 September 2017

Ramnath Misra

6

1 reference

3 September 2017

Padmanabha D. Shenoy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837499

12 July 2024

Lalan K. Jha

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837499

12 July 2024

Sunil K. Choudhary

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837499

12 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20837499

12 July 2024

publication date

12 September 2010

1 reference

full work available at URL

3 September 2017

https://academic.oup.com/rheumatology/article-pdf/49/12/2420/17387001/keq291.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837499

http://rheumatology.oxfordjournals.org/cgi/content/abstract/49/12/2420

12 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20837499

http://academic.oup.com/rheumatology/article-pdf/49/12/2420/17387001/keq291.pdf

12 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEQ291

12 July 2024

1 reference

3 September 2017

volume

49

1 reference

3 September 2017

issue

12

1 reference

3 September 2017

page(s)

2420-2428

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

3 September 2017

1 reference

Diagnosis and management of scleroderma peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Effects of cilostazol in patients with Raynaud's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Vascular disease in scleroderma: mechanisms of vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Nitric oxide in wound-healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ291

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEQ291

Clinical monograph for drug formulary review: erectile dysfunction agents

12 July 2024

4

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEQ291

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study

12 July 2024

9

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEQ291

Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group

12 July 2024

16

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEQ291

12 July 2024

Identifiers

1 reference

3 September 2017

1 reference